GB Diagnostics is proud to be involved in the research and development of monoclonal antibodies specific to protein epitopes the parts of an antigen that an antibody attaches to. To this end, GB Diagnostics is completing validation of a new, ultra-high sensitivity fluorescence Enzyme Immunoassay (FEIA). The EIA process uses enzyme labelled antibodies and antigens to detect the […]
Continue readingContact Us
For more information, please fill out the form below.
Continue readingGB Diagnostics
ABOUT US
GB Diagnostics is a North American biotech company specializing in the development and use of pioneering, state of the art, Immunofluorescence technologies for lab-based assays and Point of Use (PoU) devices.
Our high sensitivity lab-based assays are built on a platform utilizing proprietary technology to perform Fluorescent EIA(FEIA) and fluorescence-binding assays at ultra-low analyte detection levels. The tests are designed to offer ease of use and low cost to the customer.
The GB Diagnostics PoU collection device uses a quantitative/semi-quantitative test platform designed to measure protein biomarkers in saliva, among other body fluids, at levels currently undetectable in the PoU marketplace. Developed with patent-pending technology meant to address these present challenges, GB Diagnostics PoU device promises to be a game changer in its field.
At the heart of GB Diagnostics is a commitment to the research, development, promotion and sales of the highest quality products and services for the benefit of the diagnostics community.